European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis

European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis
The European Union has approved Amgen's Amgevita, a biosimilar to Humira (adalimumab), as a treatment for inflammatory bowel diseases (IBDs) such as Crohn's and ulcerative colitis. The European Commission decision applies to moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis in adults, and moderate-to-severe Crohn's in children at least 6 years old. Amgevita can also be used to treat several conditions besides inflammatory IBDs in adults and children, the EU added. The commission approved its use in adults with moderate-to-severe rheumatoid arthritis, psoriatic arthriti, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, and panuveitis. Doctors can now use Amgevita to treat children 4 and older with severe chronic plaque psoriasis, 6 and older with enthesitis-related arthritis, and 2 and older with polyarticular juvenile idiopathic arthritis. The U.S. Food and Drug Administration (FDA) approved Amgetiva in September 2016. It is known as adalimumab-atto in the United States. Europe's approval was based on the results of two Phase 3 clinical trials of Amgevita's use as a treatment for moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis patients. Like Humira, Amgevita is a monoclonal antibody that targets tumor necrosis factor alpha. TNF alpa is a pro-inflammatory mediator that plays a critical role in inflammatory bowel disease. Amgevita may benefit adults with moderate to severe active ulcerative colitis who have failed to respond fully to conventional treatments, including
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *